BioMarin Pharmaceutical Inc.
About BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company dedicated to transforming lives through genetic discovery. In 1997, the company was founded to make a big difference in small patient populations, focusing on giving much-needed attention to the underserved communities of those with rare diseases. BioMarin sought to help patients whose voices could not always be heard and treat conditions that were not always in mainstream medical conversations. Throughout its history, BioMarin has worked tirelessly to make a difference by pursuing bold science. The company’s first approved therapy was inspired by a father who refused to accept there was no therapy for his son’s rare diagnosis. That relentless pursuit to change the course of his son’s future through the power of science is at the core of who BioMarin is today.
Through the company’s expertise in genetics and molecular biology, BioMarin has developed eight first or best-in-class targeted therapies that address the root cause of the conditions it seeks to treat, helping to better the lives of those struggling with rare genetic disease. The company’s purposeful and scientifically precise team of physicians and scientists has honed each treatment modality to seek transformative therapies.
Now, BioMarin seeks to make an even greater impact by applying the same science-driven, patient-forward approach that propelled the last 25 plus years of drug development to larger genetic disorders, as well as genetic subsets of more common conditions. Each drug candidate pursued is guided by a fundamental understanding of the genetics and underlying biology of the condition it will address. The company believes that applying its knowledge to make a transformative impact is not just a calling, but an obligation to those who will benefit most. The more innovative solutions developed, the more lives BioMarin can impact.
841 articles about BioMarin Pharmaceutical Inc.
-
BioMarin Pharmaceutical Inc. Denies Compassionate Use to Cancer Patient
9/10/2013
-
BioMarin Pharmaceutical Inc. to Host a Research and Development Day on September 17th
9/5/2013
-
BioMarin Pharmaceutical Inc. to Attend Upcoming Conferences: Citi Biotech Day, BioMarin Pharmaceutical Inc. Global Healthcare Conference and Baird Healthcare Conference
9/3/2013
-
BioMarin Pharmaceutical Inc. Appoints Richard Ranieri as Senior Vice President, Human Resources and Corporate Affairs
9/3/2013
-
BioMarin Pharmaceutical Inc. Announces Oral Presentation of BMN 673 Most Recent Data on Breast and Ovarian Cancers at the European Cancer Congress 2013
8/19/2013
-
BioMarin Pharmaceutical Inc. Provides BMN 673 Program Update
7/26/2013
-
BioMarin Pharmaceutical Inc. Announces Second Quarter 2013 Financial Results
7/26/2013
-
BioMarin Pharmaceutical Inc. to Host Second Quarter 2013 Financial Results Conference Call and Webcast on Thursday, July 25 at 5:00 p.m. ET
7/3/2013
-
BioMarin Pharmaceutical Inc. to Present at the Goldman, Sachs & Co. Global Healthcare Conference
6/6/2013
-
BioMarin Pharmaceutical Inc. Initiates Phase 3 Trial for PEG-PAL for the Treatment of PKU
6/5/2013
-
BioMarin Pharmaceutical Inc. Provides Preliminary Data on Ongoing Phase 1/2 Trial for BMN 673 for the Treatment of Solid Tumors at 2013 American Society of Clinical Oncology Annual Meeting
6/3/2013
-
BioMarin Pharmaceutical Inc. to Present at the Jefferies and Co. Global Healthcare Conference
5/31/2013
-
What Mystery $7 Billion Life Science Company is Moving to SF's Mission Bay? Is it Illumina, Inc.? BioMarin Pharmaceutical Inc.?
5/30/2013
-
BioMarin Pharmaceutical Inc. Release: FDA Accepts Vimizim BLA and Grants Priority Review Designation
5/30/2013
-
BioMarin Pharmaceutical Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
5/20/2013
-
BioMarin Pharmaceutical Inc. Announces BMN-673 Data in Breast and Ovarian Cancers to be Released at American Society of Clinical Oncology
5/17/2013
-
BioMarin Pharmaceutical Inc. to Present at the UBS Global Healthcare Conference
5/14/2013
-
BioMarin Pharmaceutical Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
4/18/2013
-
BioMarin Pharmaceutical Inc. Submits CTA for BMN-190 for Batten Disease
4/1/2013
-
BioMarin Pharmaceutical Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
3/19/2013